India likely to get Omicron-specific vaccine by year-end, says SII chief

SII is working with Novavax to bring the Omicron-specific vaccine, as the nation continues to record a surge in the number of Covid-19 cases

Adar Poonawalla
Adar Poonawalla (Photo: Kamlesh Pednekar)
BS Web Team
2 min read Last Updated : Aug 15 2022 | 7:48 PM IST
The Serum Institute of India (SII) is currently working on an Omicron-specific vaccine, which is expected to be launched by the end of the year, said CEO Adar Poonawalla said on Monday.

Serum Institute is working with Novavax to bring the Omicron-specific vaccine, as India continues to record a surge in the number of Covid-19 cases. The new vaccine will be "specific to the BA5 sub-variant of Omicron, for which the UK has approved an updated Moderna vaccine. The bivalent vaccine targets the Omicron variant as well as the original form," NDTV reported.

Also Read: What is Chikungunya? Symptoms, treatment, prevention, and other details

Poonawalla said that Omicron-specific vaccine is going to be equally important as a booster dose, given that Omicron is 'not mild' and presents itself like a serious flu. "It is important for India to boost with an Omicron-specific vaccine", he added. 

Emerged in late 2021, the Omicron sub-variant of the coronavirus had a faster transmission rate and was declared as a variant of concern by the World Health Organisation. It, however, is less severe as compared to the Delta variant.

According to a report published in Economic Times, the UK drug regulator, on Monday said that it has approved an updated Moderna vaccine, which works against the Omicron sub-variant of the Coronavirus, as well as against the original form. 

In a statement, the Medicine and Healthcare products Regulatory Agency said, it had approved the vaccine for adult booster doses "after it was found to meet the regulator's standards of safety, quality and effectiveness" and to prompt a "strong immune response" against both strains.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusOmicronSerum Institute of IndiaCoronavirus VaccinecoronaDrug makersUK drugs regulatorVaccinemedicinehealthcareIndian healthcare

Next Story